Title:
アジュバントにより増強される免疫療法
Document Type and Number:
Japanese Patent JP2005532296
Kind Code:
A
Abstract:
An improved method is provided for treating disease states characterized by the existence of pathogenic cell populations. In accordance with the improved method, cell-targeted ligand-immunogen or ligand-hapten complexes are administered to a diseased host to redirect the host immune response to the pathogenic cells which have an accessible binding site for the ligand. The method comprises the step of administering to the host a ligand-immunogen or ligand-hapten conjugate composition comprising a complex of the ligand and the immunogen or hapten wherein the immunogen/hapten is recognized by an endogenous antibody in the host or directly by an immune cell in the host. The improvement to the method comprises the step of using a TH1-biasing adjuvant to enhance the immune response to cell-bound ligand-immunogen or ligand-hapten conjugates.
Inventors:
Lou, Infan
Application Number:
JP2003586306A
Publication Date:
October 27, 2005
Filing Date:
April 16, 2003
Export Citation:
Assignee:
End Site, Incorporated
International Classes:
A61K31/704; A61K38/19; A61K39/00; A61K39/385; A61K39/39; A61K47/48; A61P31/00; A61P31/04; A61P31/10; A61P31/12; A61P31/14; A61P31/20; A61P31/22; A61P33/00; A61P33/02; A61P33/04; A61P33/10; A61P35/00; A61P35/02; A61K45/00; A61P37/04; A61P43/00; C07J63/00; (IPC1-7): A61K39/00; A61K39/39; A61K45/00; A61P31/00; A61P31/04; A61P31/10; A61P31/12; A61P31/14; A61P31/20; A61P31/22; A61P33/00; A61P33/02; A61P33/04; A61P33/10; A61P35/00; A61P35/02; A61P37/04; A61P43/00
Foreign References:
| WO2001074382A1 | 2001-10-11 |
Other References:
JPN7009002024; Ｌｕ Ｙ， Ｌｏｗ ＰＳ: 'Ｆｏｌａｔｅ ｔａｒｇｅｔｉｎｇ ｏｆ ｈａｐｔｅｎｓ ｔｏ ｃａｎｃｅｒ ｃｅｌｌ ｓｕｒｆａｃｅｓ ｍｅｄｉａｔｅｓ ｉｍｍｕｎｏｔｈｅｒａｐｙ ｏｆ ｓｙｎｇｅｎｅｉｃ ｍｕｒｉｎｅ ｔｕｍｏｒ' Ｃａｎｃｅｒ Ｉｍｍｕｎｏｌ Ｉｍｍｕｎｏｔｈｅｒ． ５１（３）, 20020319, １５３-１６２
JPN7009002025; Ｋｉｍ ＳＫ， Ｒａｇｕｐａｔｈｉ Ｇ， Ｃａｐｐｅｌｌｏ Ｓ， Ｋａｇａｎ Ｅ， Ｌｉｖｉｎｇｓｔｏｎ ＰＯ: 'Ｅｆｆｅｃｔ ｏｆ ｉｍｍｕｎｏｌｏｇｉｃａｌ ａｄｊｕｖａｎｔ ｃｏｍｂｉｎａｔｉｏｎｓ ｏｎ ｔｈｅ ａｎｔｉｂｏｄｙ ａｎｄ Ｔ-ｃｅｌｌ ｒｅｓｐｏｎｓｅ ｔｏ ｖａｃｃｉｎａｔｉｏｎ ｗｉｔ' Ｖａｃｃｉｎｅ １９（４-５）, 2001, ５３０-５３７
JPN6010063280; ＲＡＧＵＰＡＴＨＩ，Ｇ． ｅｔ ａｌ: 'Ａ ｐｒｅｃｌｉｎｉｃａｌ ｓｔｕｄｙ ｃｏｍｐａｒｉｎｇ ａｐｐｒｏａｃｈｅｓ ｆｏｒ ａｕｇｍｅｎｔｉｎｇ ｔｈｅ ｉｍｍｕｎｏｇｅｎｉｃｉｔｙ ｏｆ ａ ｈｅｐｔａｖａｌｅｎｔ ＫＬＨ-ｃｏｎｊ' Ｃａｎｃｅｒ Ｉｍｍｕｎｏｌ Ｉｍｍｕｎｏｔｈｅｒ Ｖｏｌ．５２， Ｎｏ．１０, 2003, ｐ．６０８-１６
JPN6010063281; ＳＬＯＶＩＮ，Ｓ．Ｆ． ｅｔ ａｌ: 'Ａ ｂｉｖａｌｅｎｔ ｃｏｎｊｕｇａｔｅ ｖａｃｃｉｎｅ ｉｎ ｔｈｅ ｔｒｅａｔｍｅｎｔ ｏｆ ｂｉｏｃｈｅｍｉｃａｌｌｙ ｒｅｌａｐｓｅｄ ｐｒｏｓｔａｔｅ ｃａｎｃｅｒ： ａ ｓｔｕｄｙ ｏｆ' Ｖａｃｃｉｎｅ Ｖｏｌ．２３， Ｎｏ．２４, 2005, ｐ．３１１４-２２
JPN6010063283; ＧＡＴＨＵＲＵ，Ｊ．Ｋ． ｅｔ ａｌ: 'Ｉｄｅｎｔｉｆｉｃａｔｉｏｎ ｏｆ ＤＨＢｃＡｇ ａｓ ａ ｐｏｔｅｎｔ ｃａｒｒｉｅｒ ｐｒｏｔｅｉｎ ｃｏｍｐａｒａｂｌｅ ｔｏ ＫＬＨ ｆｏｒ ａｕｇｍｅｎｔｉｎｇ ＭＵＣ１ ａｎｔｉｇｅｎｉｃ' Ｖａｃｃｉｎｅ Ｖｏｌ．２３， Ｎｏ．３９, 2005, ｐ．４７２７-３３
JPN7009002025; Ｋｉｍ ＳＫ， Ｒａｇｕｐａｔｈｉ Ｇ， Ｃａｐｐｅｌｌｏ Ｓ， Ｋａｇａｎ Ｅ， Ｌｉｖｉｎｇｓｔｏｎ ＰＯ: 'Ｅｆｆｅｃｔ ｏｆ ｉｍｍｕｎｏｌｏｇｉｃａｌ ａｄｊｕｖａｎｔ ｃｏｍｂｉｎａｔｉｏｎｓ ｏｎ ｔｈｅ ａｎｔｉｂｏｄｙ ａｎｄ Ｔ-ｃｅｌｌ ｒｅｓｐｏｎｓｅ ｔｏ ｖａｃｃｉｎａｔｉｏｎ ｗｉｔ' Ｖａｃｃｉｎｅ １９（４-５）, 2001, ５３０-５３７
JPN7009002025; Ｋｉｍ ＳＫ， Ｒａｇｕｐａｔｈｉ Ｇ， Ｃａｐｐｅｌｌｏ Ｓ， Ｋａｇａｎ Ｅ， Ｌｉｖｉｎｇｓｔｏｎ ＰＯ: 'Ｅｆｆｅｃｔ ｏｆ ｉｍｍｕｎｏｌｏｇｉｃａｌ ａｄｊｕｖａｎｔ ｃｏｍｂｉｎａｔｉｏｎｓ ｏｎ ｔｈｅ ａｎｔｉｂｏｄｙ ａｎｄ Ｔ-ｃｅｌｌ ｒｅｓｐｏｎｓｅ ｔｏ ｖａｃｃｉｎａｔｉｏｎ ｗｉｔ' Ｖａｃｃｉｎｅ １９（４-５）, 2001, ５３０-５３７
JPN6010063280; ＲＡＧＵＰＡＴＨＩ，Ｇ． ｅｔ ａｌ: 'Ａ ｐｒｅｃｌｉｎｉｃａｌ ｓｔｕｄｙ ｃｏｍｐａｒｉｎｇ ａｐｐｒｏａｃｈｅｓ ｆｏｒ ａｕｇｍｅｎｔｉｎｇ ｔｈｅ ｉｍｍｕｎｏｇｅｎｉｃｉｔｙ ｏｆ ａ ｈｅｐｔａｖａｌｅｎｔ ＫＬＨ-ｃｏｎｊ' Ｃａｎｃｅｒ Ｉｍｍｕｎｏｌ Ｉｍｍｕｎｏｔｈｅｒ Ｖｏｌ．５２， Ｎｏ．１０, 2003, ｐ．６０８-１６
JPN6010063281; ＳＬＯＶＩＮ，Ｓ．Ｆ． ｅｔ ａｌ: 'Ａ ｂｉｖａｌｅｎｔ ｃｏｎｊｕｇａｔｅ ｖａｃｃｉｎｅ ｉｎ ｔｈｅ ｔｒｅａｔｍｅｎｔ ｏｆ ｂｉｏｃｈｅｍｉｃａｌｌｙ ｒｅｌａｐｓｅｄ ｐｒｏｓｔａｔｅ ｃａｎｃｅｒ： ａ ｓｔｕｄｙ ｏｆ' Ｖａｃｃｉｎｅ Ｖｏｌ．２３， Ｎｏ．２４, 2005, ｐ．３１１４-２２
JPN6010063283; ＧＡＴＨＵＲＵ，Ｊ．Ｋ． ｅｔ ａｌ: 'Ｉｄｅｎｔｉｆｉｃａｔｉｏｎ ｏｆ ＤＨＢｃＡｇ ａｓ ａ ｐｏｔｅｎｔ ｃａｒｒｉｅｒ ｐｒｏｔｅｉｎ ｃｏｍｐａｒａｂｌｅ ｔｏ ＫＬＨ ｆｏｒ ａｕｇｍｅｎｔｉｎｇ ＭＵＣ１ ａｎｔｉｇｅｎｉｃ' Ｖａｃｃｉｎｅ Ｖｏｌ．２３， Ｎｏ．３９, 2005, ｐ．４７２７-３３
JPN7009002025; Ｋｉｍ ＳＫ， Ｒａｇｕｐａｔｈｉ Ｇ， Ｃａｐｐｅｌｌｏ Ｓ， Ｋａｇａｎ Ｅ， Ｌｉｖｉｎｇｓｔｏｎ ＰＯ: 'Ｅｆｆｅｃｔ ｏｆ ｉｍｍｕｎｏｌｏｇｉｃａｌ ａｄｊｕｖａｎｔ ｃｏｍｂｉｎａｔｉｏｎｓ ｏｎ ｔｈｅ ａｎｔｉｂｏｄｙ ａｎｄ Ｔ-ｃｅｌｌ ｒｅｓｐｏｎｓｅ ｔｏ ｖａｃｃｉｎａｔｉｏｎ ｗｉｔ' Ｖａｃｃｉｎｅ １９（４-５）, 2001, ５３０-５３７
Attorney, Agent or Firm:
Isshiki International Patent Service Corporation